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Abstract
Background: Mantle cell lymphoma (MCL) is a rare variety of non-Hodgkin's lymphoma which
originates from CD5+ B-cell population in the mantle zones of lymphoid follicles. Coexistence of
such tumours in the axillary lymph nodes with invasive breast cancers without prior history of
adjuvant chemotherapy or radiotherapy has not been previously reported in literature.
Case report: We report a rare case of breast cancer co-existing with stage I mantle cell
lymphoma of the ipsilateral axillary lymph node detected fortuitously by population screening.
Conclusion: Though some studies have tried to prove breast carcinomas and lymphomas to share
a common molecular or viral link, more research needs to be done to establish whether such a link
truly exists.
Background
Mantle cell lymphoma (MCL) is a rare type of B-cell lym-
phoma, which comprises 5–10% of all malignant lym-
phomas [1]. These tumours present in older adults with a
median age of 65 and are often at an advanced stage (III
or IV) when diagnosed [1,2]. Breast cancer patients have
increased risks of Non-Hodgkin's lymphoma following
treatment with radio and chemotherapy but coexistence
of the two diseases is rare [3]. In the literature, no case of
breast cancer occurring simultaneously with axillary man-
tle cell lymphoma has been reported previously and we
present such a case here where both pathologies coexisted
without any history of adjuvant therapy.
Report
A 67-year-old postmenopausal lady presented herself for
breast screening and the mammogram revealed a radi-
odense opacity over the upper outer quadrant of her left
breast suspicious of carcinoma.
She had no previous breast problems and no family his-
tory of note. She was para 4, had her first pregnancy aged
22, had breast fed all her children, had been on oral con-
traceptive pills for 20 years and was taking Hormone
Replacement Therapy (HRT) for 10 years which had been
withdrawn a few months back. She was a non-smoker, a
moderate drinker and had no significant medical prob-
lems. There was no palpable lump over her left breast and
clinically she was aymptomatic without the presence of
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any B symptoms (night sweats, fever or loss of weight)
and did not have lymphadenopathy or
hepatosplenomegaly.
A core biopsy was undertaken which revealed grade II
invasive ductal carcinoma of no special type. Her full
blood count and liver function tests were within normal
limits and chest X-ray was unremarkable. She underwent
stereotactic needle localisation and wide local excision of
the lump with axillary sampling. Per-operatively it was
noted that two axillary lymph nodes were enlarged
though soft in consistency. Histology of the breast lump
revealed a 10 mm, grade 2 invasive ductal carcinoma that
was positive for oestrogen receptors. The histology of the
four axillary lymph nodes removed during the procedure
showed diffuse proliferation of small to medium sized
atypical lymphocytes with irregular nuclear contours,
small nucleoli and scant cytoplasm suggesting malignant
lymphoma. They were positive for pan B-cell antigens
CD19, CD20, CD22 and negative for cytokeratin, oestro-
gen or progesterone receptors on immunohistochemistry
and demonstrated Cyclin D1 (bcl 1) nuclear expression
that was pathognomonic of mantle cell lymphoma.
She was referred to the haematology and oncology teams
and subsequently underwent a computerised tomo-
graphic (CT) scan of her thorax, abdomen and pelvis,
which revealed a small node in each axilla. A bone mar-
row aspiration was done which revealed no evidence of
lymphoma. Repeat full blood count and biochemistry
including Lactate Dehydrogenase (LDH) were also within
normal limits. The histopathogy slides were reviewed and
the initial diagnosis of mantle cell lymphoma was con-
firmed. She was subsequently started on Tamoxifen and
adjuvant radiotherapy for definitive treatment of her
breast cancer and following a multi-disciplinary meeting,
a wait and watch policy with close monitoring by the sur-
gical and oncology teams was employed with regard to
her lymphoma given the fact that it was diagnosed at such
an early stage.
Discussion
MCL is a rare type of B-cell lymphoma comprising 5–10%
of all malignant lymphomas [1]. Because this lymphoma
has been noticed and described recently, knowledge
regarding MCL is limited. It was originally classified as a
low-grade lymphoma, but recent reports of outcome indi-
cate that most cases behave as intermediate-grade because
it has neither the long survival of low-grade tumours nor
the response to chemotherapy of high-grade lymphomas
[2]. These tumours present in older adults (median age
65) and are commoner in men (male: female; 2.3:1) [2].
The disease is generally widespread at diagnosis(Stage III
or IV) with invasion of the lymph nodes, spleen, bone
marrow, gastrointestinal tract, peripheral blood and Wal-
deyer's ring and presence of B symptoms like weight loss,
fever and night sweats [2].
A chromosomal translocation t(11; 14) involves the bcl-1
locus (chromosome 11) and the immunoglobulin heavy
chain locus (chromosome 14) in such patients. The trans-
location causes overexpression of the proline-rich attach-
ment domain PRAD-1 gene that encodes Cyclin D1, a
promoter of progression of the cell cycle. The transloca-
tion can only be detected in half the patients, but the over-
production of Cyclin D1 is a diagnostic feature [4].
Four histologic subtypes have been described – Nodular,
Diffuse, Mantle Zone and Blastic. It has been reported that
the Mantle Zone variant may have a more indolent course
than the other subtypes while Blastic appears to have the
poorest prognosis [1,5]. Histologically, there is a mixture
of small to medium sized atypical lymphocytes with
slightly irregular contours, condensed chromatin, incon-
spicuous nucleoli and scanty cytoplasm [5]. They express
a variety of B-cell antigens like CD19, CD20 and CD22 as
well as CD5 and CD43 when stained for immunohisto-
chemistry [2] and Cyclin D1 immunopositivity, if present,
is pathognomonic [2,5].
MCL is currently incurable [6]. Treatment is mainly with
chemotherapy though controversy rages whether CHOP
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(cyclophosphamide, adriamycin, vincristine, prednisone)
or CVP (cyclophosphamide, vincristine, prednisone)
regime is better. A small subgroup can be managed by
observation only [1,6]. Two studies have shown survival
benefits with an anthracyclin based regimen [6]. Overall,
MCL responds to chemotherapy initially but usually
recurs within 18 months and has the shortest median sur-
vival of all lymphomas with a median survival of 3–5
years regardless of treatment [5]. High-dose chemother-
apy with stem cell transplant and allogenic bone marrow
transplants has shown no survival benefits and research is
currently under way to find a better treatment option [6].
Conclusion
Breast cancer patients have an increased risk of developing
second malignancies following adjuvant chemotherapy
and radiotherapy, including leukaemia and non-Hodg-
kin's lymphoma [3]. These generally appear 2–5 years fol-
lowing treatment. Co-existing mantle cell lymphoma and
breast cancer has never been reported previously in litera-
ture and whereas this case might be a mere co-incidence,
it also raises the possibility of a common link between
these two cancers. Recent research has implicated the
oncogenic Epstein-Barr virus as the possible agent respon-
sible for spread of both invasive breast cancer and lym-
phomas through a latent antigen EBNA-3C which
interacts specifically with the human metastatic suppres-
sor protein Nm23-H1 and reverses its ability to stop
migration of lymphoma and breast carcinoma cells [7].
Though more research needs to be done to come up with
a definitive answer, it would be interesting to see if indeed
there is a molecular link between such co-existing cancers





SDR conceived the study, prepared the manuscript and
conducted the literature search on this topic.
JAS prepared the histology and immunohistochemistry
slides and reviewed them to confirm the diagnosis.
JS reviewed the radiology slides and performed the needle
localisation on this patient before surgery.
SNS performed the initial operation, has been following
up the patient in his clinic and participated in the final
design and review of the manuscript
References
1. Argatoff L, Connors J, Klasa R, Horsman D, Gascoyne R: Mantle cell
lymphoma: a clinicopathologic study of 80 cases. Blood 1997,
89:2067-2078.
2. Fisher R: Mantle cell lymphoma: classification and therapeutic
implications. Ann Oncol 1996, 7(Suppl 6):S35-S39.
3. Harvey EB, Brinton LA: Second cancer following cancer of the
breast. Natl Cancer Inst Monogr 1985, 68:99-112.
4. Majlis A, Pugh W, Rodriguez M, Benedict W, Cabanillas F: Mantle
cell lymphoma: correlation of clinical outcome and biologic
features with three histologic variants.  J Clin Oncol 1997,
15:1664-1671.
5. Meusers P, Hense J, Brittinger G: Mantle cell lymphoma: diagnos-
tic criteria, clinical aspects and therapeutic problems. Leuke-
mia 1997, 11(Suppl 2):S60-S64.
6. Densmore JJ, Williams ME: Mantle cell lymphoma.  Curr Treat
Options Oncol 2003, 4:281-287.
7. Subramaniam C, Cotter MA, Robertson ES: Epstein-Barr virus
nuclear protein EBNA-3C interacts with the human meta-
static suppressor Nm 23-H1: A molecular link to cancer
metastasis. Nature Medicine 2001, 7:350-355.
Photomicrograph of the axillary lymphnode showing sheets  of abnormal, irregular and pleomorphic lymphocytes with  scant cytoplasm effacing normal lymphoid architecture (Hae- matoxylin and Eosin × 400) Figure 2
Photomicrograph of the axillary lymphnode showing sheets 
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